Establishing noninvasive and low-cost data collection based on childbirth narratives for the identification of women with CB-PTSD could serve as an important first step to complement more extensive methods.
Loss of at least one night’s sleep at the time of labor and delivery is a potent risk factor for postpartum psychosis in women with bipolar disorder.
Dr. Marlene Freeman recently shared her insights on Psychiatric Medications and Considerations for Individuals Across Pregnancy, the Postpartum, and Reproductive Years with the National Alliance on Mental Illness on March 7, 2024.
Women who experienced depression during pregnancy were about four times as likely to experience PPD compared to women with no depression during pregnancy, with greater risk associated with depression during the first and third trimesters.
Postpartum SSRI treatment mitigated the negative associations between PPD and later maternal depression, partner relationship satisfaction, and child externalizing problems and ADHD symptoms up to 5 years after childbirth.
The largest GWAS study to date provides evidence that despite a high correlation with MDD, PPD may have unique genetic components.
The package insert advises patients to avoid driving and other potentially hazardous activities after taking zuranolone.
Machine learning can be used to analyze data contained within the electronic health record to accurately predict which individuals are at increased risk for postpartum depression.
A wide range of delivery options may be effective for addressing symptoms of depression in perinatal individuals, and could therefore be leveraged to expand access to treatments.
A routinely administered single-item measure of sleep disturbance could identify pregnant individuals who are at risk for PPD and may benefit from depression prevention efforts.
